Drugs In The News

Edward McLean, PharmD Candidate; Marcus Campbell, PharmD June 21, 2013 According to the data from the Center for Disease Control (CDC) on communicable diseases, the incidence of pertussis cases has been increasing over the past several years, most notably among the infant population.1 In order to combat this rising trend, The Advisory Committee on Immunization practices

Cierra Harden, PharmD Candidate; Katherine Tromp, PharmD; Marcus Campbell, PharmD Each year in the United States the influenza virus causes a contagious respiratory illness (“the flu”) with significant morbidity and mortality. People who become infected often have symptoms of fever, cough, sore throat, and/or malaise. Hospitalization is sometimes required, typically in patients who are older,

Yevgeniy Lyutov; Mitchelle Rodriguez; Minh Trinh; Tam Tran, PharmD Candidates; Marcus W. Campbell PharmD, BC-ADM  Hydrocodone is a semisynthetic opioid agonist which works by binding to opiate receptors in the CNS, altering the perception of and response to pain as well as suppress the cough in the medullary center. Hydrocodone is commonly prescribed for analgesia

Yevgeniy Lyutov, PharmD Candidate; Mitchelle Rodriguez, PharmD Candidate; Katherine Tromp, PharmD Prescription drug abuse is the intentional use of a medication without a prescription, in a way other than as prescribed, or for the experience or feeling it causes.1 Prescription drug misuse can consists of using a medication in a manner or at a dose that

Brett Snyderman, PharmD Candidate; Marcus Campbell, BC-ADM A 26-week, open-label, multi-center, randomized, parallel-group trial sought to compare once weekly exenatide versus once daily liraglutide in patients with type 2 diabetes. The results of the DURATION-6 trial were published in the January 12th issue of The Lancet in the article titled “Exenatide once weekly versus liraglutide once

Ketal Patel, PharmD Candidate; Marcus Campbell, PharmD, BC-ADM Diabetes mellitus (DM) is highly prevalent in the United States. According to American Diabetes Association (ADA), 25.8 million children and adults in the United States have diabetes.1 There are multiple classes of oral agents that are used for glycemic control.  One of the newest classes is the SGLT-2 (sodium-glucose

Lucas Reinhartz, Kimberly Crowell, Kristin Ludolph, Courtney Roberts, PharmD Candidates Ryan Wargo, PharmD, BCACP; Marcus Campbell, PharmD, BC-ADM The American Diabetes Association (ADA) issues clinical practice guidelines for the “Standards of Medical Care in Diabetes” every January. Some of the major revisions to the 2013 guideline include recommendations for a less stringent systolic blood pressure

Apixiban for Non-Valvular Afib

Tuesday, 22 January 2013

Brett Snyderman, MS, PharmD Candidate On December 28th, 2012 the FDA announced the approval of Eliquis (apixaban), an oral Factor Xa inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation1. The approval of Eliquis was based on two pivotal clinical trials, the ARISTOTLE and AVERROES trials. The Apixaban

Tamiflu Expanded Indication

Tuesday, 22 January 2013

Ketal Patel, PharmD Candidate Tamiflu® (oseltamavir) is an antiviral agent that is indicated for prophylaxis of influenza and treatment of acute illness caused by influenza A or B viral infection with symptom onset within 48 hours.   As of December 21, 2012 the FDA has expanded the indication of Tamiflu for treatment of influenza infection to include

NSAIDS and ACE-inhibitors

Monday, 21 January 2013

Kathryn Samai, PharmD, BCPS; Spencer Haslam, PharmD Candidate The concomitant use of NSAIDs and ACE inhibitor (ACEI) has been associated with reducing the anti-hypertensive effects of the ACEI, as well as carrying the potential to inflict acute renal damage. The presumed mechanism of these effects on the kidneys and blood pressure stem from NSAIDs affect